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Purpose: The aim of the present study is to investigate the effects of biological agents (BAs) on human
chondrocytes and osteocytes in vitro.
Methods: Primary cell cultures obtained from gonarthrosis patients were divided into four groups, two of which
were designated as control cultures of chondrocyte and osteocyte, and the other two groups were exposed to BAs
administered via the culture medium. Cultured cells were characterized by immunophenotyping. Before and after
administration of the agents, the cultures were observed by inverted and environmental scanning electron
microscopy (ESEM). The number of live cells and the proliferation rate were monitored by MTT assay.
Results: Rituximab and adalimumab were the least toxic agents to chondrocytes, whereas adalimumab and
etanercept were to osteocytes.
Conclusion: During periods of intense active inflammation, the concentration of the preferred BAs after inhibition
of inflammation needs to be emphasized when their effects on cartilage and bone tissue are considered at the
cellular level if the clinical practice is to continue.
Keywords: Biological agents, Chondrotoxicity, Osteotoxicity, Primary cell cultureIntroduction
Rheumatic diseases are systemic inflammatory condi-
tions that may cause severe joint degeneration and are
associated with high morbidity and mortality rates [1].
In recent years, in an attempt to prevent joint degen-
eration associated with rheumatic diseases, drugs
known as biological agents (BAs) have been approved
for clinical use in the treatment of rheumatic diseases,
and their usage is increasing [2]. Recently, personal-
ized medical treatment has become more desirable,
making the careful identification of the adverse effects
of BAs a matter of great importance [1].
Disease-modifying anti-rheumatic drugs are declared
as the traditional treatment of rheumatic diseases and,
even if these drugs reduce the symptoms of the disease
in a long-term, they have limited effects to terminate the
disease completely [3]. Involved in exceeding this limit,* Correspondence: misyar2003@yahoo.com
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ogy, have become the hope for the prevention of inflam-
matory diseases [4], and the use of high-quality tumor
necrosis factor (TNF)-α inhibitors, interleukin (IL-1)
blockers, anti-B cell (CD20) antibody, and T cell co-
stimulatory modulators has created a revolution in the
treatment [5]. However, although the efficiency of these
agents in the treatment is well known, they also cause
serious side effects because of their immunosuppressive
activity [6–11], and hence, the necessity of a comparison
of side-effect profiles based on clinical observations is
emphasized [7]. Indeed, planning a treatment at the cel-
lular level to regain the functionality of tissues or organs
is mentioned nowadays, as indicated in literature, and a
comparison of clinical observations may not be suffi-
cient. Therefore, additional researches based on cellular
level and pharmaco-molecular approach are still needed,
before clinical applications of BAs.
In the present study, we aim to observe the effects of
three TNF inhibitors, etanercept (ETA) (soluble TNF
receptor fusion protein (p75-IgG fusion protein)),le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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body), and adalimumab (ADA) (recombinant human
IgG1 monoclonal antibody), and two IL-1 antagonists,
abatacept (ABA) (CTLA4-IgG1 fusion protein) and ri-
tuximab (RIT) (anti-CD20 monoclonal antibody; used in
B-cell-inhibiting treatments on human primary chondro-
cytes and osteocytes in vitro). Using these methods, we
aim to evaluate the toxicity and effects of the BAs on
the viability and proliferation of the cultured cells.
Methods
Ethics approval and permission
This scientific research project (2014-28/23) was ap-
proved by the Local Scientific Research Ethics Commit-
tee of Gulhane Military Medical Academy (GMMA) on
February 27, 2014, with the authorization number
1491–29–14/1539. To perform molecular analyses on cel-
lular material, written informed consent was obtained from
patients. Specific BAs were numbered and researchers were
blinded to each specific BA added to each culture medium.
All experiments were carried out at least three times.
Patients and settings
Patients with a history of methotrexate, fludarabine,
cyclophosphamide, and high-dose steroid use, and
those who received an anti-pneumococcal vaccination
in the preceding 3 years were excluded from the study.
Tissues obtained from the patients with confirmed gonar-
throsis (n = 6, mean age 65 years; stage 4 gonarthrosis ac-
cording to the Kellgren-Lawrence protocol [12]) were
included in the study, and the lack of protein allergy in their
anamnesis was confirmed. Tissues resected from the distal
femur were divided into two groups to establish primary
chondrocyte and osteocyte culture. The experimental study
design and workflow are summarized in Fig. 1.
Materials
Collagenase type II enzyme (1 g, catalog # 17101–015,
Gibco), Hank’s balanced salt solution (HBSS-1X, catalog #Fig. 1 Experimental study design14025, Gibco), penicillin-streptomycin (PS), fetal bovine
serum (FBS), and Dulbecco’s modified Eagle’s medium
(DMEM 1000 mg glucose/L) were obtained from Sigma
Chemical, St. Louis, USA. Insulin-transferrin-selenious
acid (ITS) premix was obtained from Sigma-Aldrich
GmbH, Germany. MesenCult Osteogenic Stimulatory Kit
for MesenCult-XF (catalog # 05434, containing MesenCult
Basal Medium, catalog # 05431, Osteogenic Stimulatory
Supplement, catalog # 05435, and β-Glycerophosphate,
catalog # 05436) were obtained from STEMCELL Tech-
nologies, Canada. MTT assays were performed using the
Vybrant MTT Cell Proliferation assay (catalog # V-13154),
obtained from Cell Biolabs Inc., USA. The immunoflow
cytometer Beckman Coulter (catalog # Navios) was ob-
tained from France. Immunoflow CD cell surface markers
were performed using the Beckman Coulter Immunotech
company, obtained from France (catalog # A07765). The
laminar flow cabinet (Air Flow-NUVE /NF–800 R) and in-
cubator (NUVE, 06750) were obtained from Ankara,
Turkey. An Olympus CKX41 inverted microscope was
used for light microscopy, in conjunction with the Olym-
pus Cell Soft Imaging System software. A Mindray MR-
96A (China) ELISA was used for viability and cytotoxicity
measurements, while a Quanta 250 FEG (Fei Company,
Hillsboro, OR, USA) environmental scanning electron
microscope (ESEM) was used for electron microscopy.
Preparation of BAs
RIT, ADA, ABA, ETA, and INF were stored in a lam-
inar flow cabinet and dissolved using appropriate sol-
vents (0.9 % isotonic or lactated ringer or its solvents)
to obtain stock solutions at concentrations of 250, 500,
40, 50, and 100 mg/mL, respectively. Solutions were
transferred into opaque bottles, prior to labeling to be
transferred to the researchers. To apply those BAs to the
primary cell cultures, each stock solution was finally di-
luted with culture medium to reach a final concentration
of 10 μg/mL, which is consistent with the standard clinical
dosage. Concentrations of commercial stock solutions,
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Table 1.Primary cell culture
Resected tissues from both groups: bone and cartilage
were immediately transferred to the laboratory in trans-
fer medium (DMEM containing 1 % PS) under proper
conditions (4 °C). In a laminar flow cabinet, samples
were irrigated with 0.9 % isotonic sodium chloride solu-
tion to remove red blood cells and cut into small pieces
approximately 0.25 cm3 using a rongeur. Samples were
then washed in a 50-mL 0.1 % (a/h) HBSS solution. Car-
tilage and bone pieces were transferred into separate 50-
mL Falcon tubes, labeled, and processed using standard
human primary cell culture protocols. To perform en-
zymatic digestion, 200 units/mL collagenase type II en-
zyme mixture, dissolved in complete medium, was used.
Tissue samples were incubated for 16 h in a CO2 incu-
bator. Afterwards, tissue samples were centrifuged at 4 °
C at 1200 rpm for 10 min to discard collagenase. Sedi-
mented cartilage and bone tissue pellets were resus-
pended in fresh culture medium (DMEM), transferred to
flasks to obtain primary cultures.
The complete culture medium (FBS, PS, and DMEM)
was exchanged every 2 days [13]. Chondrocytes were
then maintained in ITS-supplemented DMEM for an
additional 14 days [13, 14]. Osteocytes were maintained
for 20 days, refreshing the medium (47.5-mL MSC basal
medium, 2.5-mL osteogenic stimulator supplement, 175-
μL 1 M β-glycerophosphate, FBS, PS, and DMEM) every
2 days [15]. At the end of the incubation period, cells
were detached from flasks with trypsin and counted
using a Thoma cell counting chamber in the presence of
trypan blue. To six well plates, 1.6 × 105 osteocytes and
2.9 × 105 chondrocytes were passaged and returned to
the incubator for 24 h, prior to use in exposure
experiments.Table 1 Biological agents, commercial stock solution



















Infliximab (INF) 100 0.8 10
One well 3 mL in volume will allow the BA applicationPreparation of cultures for ESEM
The culture medium was removed from the plates using
a gun pipettor. A 2.5 % glutaraldehyde solution, com-
posed of 97.5 mL of cacodylate buffer and 2.5 mL of glu-
taraldehyde, was added to the dish to cover the cells.
The glutaraldehyde solution was then removed using a
pipette gun. The cells were maintained at room
temperature for 2 h, prior to three washes using cacody-
late buffer. After the last wash, the cells were covered
with cacodylate buffer and stored at 4 °C prior to ana-
lysis [13, 16].
Characterization of cells by immunoflow cytometry
Inverted light microscopy (≠Olympus, CKX41) was used
to identify cultures containing confluent regions of ad-
herent cells. Cells were detached with trypsin-EDTA
(0.25 %), and then centrifuged at +4 °C three times,
5 min at 1200 rpm, washing with fresh medium each
time. The pellets were resuspended in freshly prepared
cell culture medium and transferred into falcon tubes.
After cell counting (between 103 and 106), the cells were
incubated with fluorescein isothiocyanate (FITC)- and
phycoerythrin (PE)-conjugated monoclonal antibodies
against cell surface markers (CD29, CD44, CD90,
CD166, HLA-DR, CD10, CD11b, CD14, CD34, CD45,
CD117), with appropriate controls, at 4 °C for 50 min,
protected from the light. The cells were washed by the
addition of PBS containing 0.1 % sodium azide, followed
by centrifugation for 5 min at 1200 rpm. The super-
natant was removed and the cells were resuspended in
assay buffer and analyzed with a flow cytometer. Results
were evaluated using the native software of the flow cyt-
ometer (Beckman Coulter Navious Software).
Analysis
Inverted light microscopy
Chondrocyte and osteocytes were imaged using an
inverted phase-contrast microscope at ×4, ×10, ×20, and
×40 magnifications, before and immediately after BA
and MTT applications. Images were analyzed using the
Olympus cell imaging software.
ESEM analysis
ESEM analysis was carried to assess the surface topog-
raphy and composition of the cells. A device with a lift-
ing system and the ability to transfer the electron beam
in a high vacuum was used. This enabled us to obtain
images of the extracellular matrix, as well as images of
characteristic cellular structures. FEG ion pumps were
used for the high vacuum. Images were recorded at a
pressure of 100–220 Pa in ESEM vacuum mode, under
magnifications of ×1000–×160,000, at resolution depths
(HFW) of 41.4 and 414 μm, at an operating voltage of
5.00 kV, and at a WD of 8.8–8.9 mm.
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Vitality tests were performed using a commercial MTT
(3-[4,5-dimethyltiazol-2-yl]-2,5- diphenyltetrazolium bro
mide; Thiazolyl blue) kit, according to the manufacturer’s
instructions. The working principle of the kit involves the
cleavage of the tetrazolium ring by mitochondrial de-
hydrogenase enzymes, yielding blue formazan crystals,
which are formed only in live cells [13–15, 17].
MTT assays were carried out on chondrocytes and os-
teocytes prior to addition of BAs. The same procedure
was then repeated 24 and 48 h after the addition of BAs.
The culture media containing BAs discarded from wells
by a gun pipettor. Instead of removed supernatant,
12 mM/5-mg MTT tetrazolium solution, 1 mL sterile
PBS, and DMEM were added, followed by SDS
(prepared by adding 10-mL 0.01 M HCl to 1-g SDS),
and then 100-μL MTT stock solution. Cultures were in-
cubated at 37 °C for 2 h protected from the light. A 500-
μL aliquot of the resultant reaction solution was re-
moved for analysis. Dimethyl sulfoxide was added to
these samples, which were incubated at 37 °C for an
additional 10 min, prior to photometric analysis of a
540-nm wavelength absorbance. For assessment of pro-
liferation, 500 μL of SDS-HCl solution was added to the
remaining cells and incubated at 37 °C for 18 h. The re-
action solution was subjected to photometric analysis at
a 570-nm wavelength. The vitality of the control group
was assumed to be 100 % prior to addition of BAs (0 h)
to the culture medium.
Five different biological agents were applied to both
chondrocyte and osteocyte cultures for 24 and 48 h. After
this period of time, MTT was applied and the cells were
incubated for an additional 12 h to monitor proliferation.
Effect on the proliferation of the 24- and 48-h application
of BA can be traced under an inverted microscope, obtain-
ing images at the 36th and 60th hours. After the 60th
hour, no live cells or proliferation were observed in the
cultures, so all tests were terminated at this time point.Statistics
Cell numbers and proliferation rates were subjected to
statistical analysis using the Minitable R15 software. To
test for differences among the groups, variance analysis
was used. Tukey’s test was used for significance differences
among means (95.0 % confidence interval). The statistical
significance level was set at p < 0.01.Results
Light microscopy and immunoflow cytometry analysis of
chondrocyte and osteocyte primary cell culture
Chondrocytes reached approximately 97 % confluence
while osteocytes 91 % in primary culture conditions, in-
dicating a healthy proliferative state (Fig. 2).Immunoflow cytometry analyses demonstrate that os-
teocytes were negative for HLA-DR, CD10, CD11b,
CD14, CD34, CD45, and CD117 (non-significant), but
positive for CD44 (99.08 %). Chondrocytes did not ex-
press CD34, CD14, and CD45 (non-significant) surface
markers, but did express CD71, CD73, and CD105
(90.73 %), all of which are typical markers for mesenchy-
mal stem cells (Fig. 3).
The decrease in the number of both chondrocyte and
osteocyte cells observed after 24 h BA application was
compared with the control groups. In terms of the pro-
liferation, 48 h application of any BAs could completely
suppress proliferation at the dose levels studied (Fig. 4).
But, for some BAs, observed impact was more dra-
matic. The effect of BA was to suppress proliferation as
well as changing the cell morphology and extracellular
matrix formed in the culture conditions. Especially, for
INF-applied chondrocytes, these effects were much more
obvious, so that cell detachment and altered cell morph-
ology were observed. However, an opposite situation was
seen in osteocytes exposed to ETA, in that morphologic-
ally occurred in these cells.
ESEM evaluation
In healthy chondrocytes and osteocytes showing osteo-
blastic activity, all natural surface characteristics are visible
in the control group images. Viable cells were observed
24 h after application of RIT and ADA to chondrocyte cul-
tures, and 24 h after application of ADA and ETA to
osteocyte cultures. Deterioration of cell surface morpholo-
gies and loss of extracellular matrix were evident in chon-
drocyte cultures after 24 h ETA, ABA, and INF exposure,
and osteocyte cultures after 24 h ABA, INF, and RIT ex-
posure. Similar results were observed 48 h after the appli-
cation. In all groups exposed to BAs, deterioration of the
cell surface and loss of matrix were observed in cultures
of both cell types (Fig. 5).
In all cases, dead cells were scattered throughout the
culture, the number of dead or live cells was decreased,
and cell morphologies were altered. In some images, cells
appeared to be contracted and to have lost their specific
morphology.
Statistical evaluation of the effects of BAs on chondrocyte
and osteocyte viability and proliferation
The MTT results supported our morphological observa-
tions. ESEM data were consistent with the results of the
MTT-ELISA viability, toxicity, and MTT-proliferation
data analyses, as well as the inverted light microscopy
images. The images supported the MTT data corre-
sponding to cartilage and bone cells before and 24 and
48 h after the application of BAs.
MTT analysis showed a decrease in cell viability in all
groups after 24 h BA application, and no viable live
Fig. 2 Inverted light microscopy images of chondrocytes and osteocytes cultures (a, b, and c are ×10, ×20, and ×40 magnification of
approximately 97 % confluent chondrocytes, respectively; d, e, and f are ×10, ×20, and ×40 magnification of approximately 91 % confluent
osteocytes, respectively)
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sorbance values are listed (Fig. 6).
Analysis of proliferation clearly showed that in all test
groups, 24 h application of BA suppressed proliferation
(absorbance values obtained at the 36th hour) which was
completely blocked after 48 h BA application (absorbance
values obtained at the 60th hour) (Fig. 7).
At 24 h, in the RIT group, more viable chondrocyte cells
were present, compared to the other groups (p < 0.01
[p = 0.0000]). RIT allowed chondrocyte proliferation up
to 36 h (p < 0.01 [p = 0.0000]). In the same period of
time, the viability rate of chondrocytes in the ADAFig. 3 Immunoflow cytometric evaluation of cell surface antigens of osteogroup was similar to the RIT group (p < 0.01 [p = 0.0000]).
In the ETA, ABA, and INF groups, the number of live
chondrocytes was lower than that of the RIT, ADA, and
control groups, suggesting that ETA, ABA, and INF
inhibited chondrocyte proliferation (p < 0.01 [p = 0.0000]).
Proliferation analysis performed 48 h after BA application
showed no living cells or proliferation in all groups, other
than the control group (p < 0.01 [p = 0.0000]).
In the osteocyte cultures, the number of live cells was
the greatest in the ADA group, followed by the ETA
group, 24 h after BA application, compared to the
control and all other groups (p < 0.01 [p = 0.0000]). Fromcyte and chondrocyte
Fig. 4 Proliferation of chondrocytes and osteocytes after 24 and 48 h BA application. Analysis of proliferation was performed in all test groups.
After administration of BAs for 24 and 48 h, cultures were allowed for proliferation for an additional 12 h. After 24 h administration of BA,
suppressed proliferation were showed by MTT assay performed at the 36th hour and complete blockage of proliferation after 48 h BA application
were showed by MTT assay performed at the 60th hour, and absorbance values were obtained
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24th hour, it was clear that proliferation occurred in ADA
and ETA groups at 36th hour (p < 0.01 [p = 0.0000]).
The viability rate of osteocytes in the ABA, INF, and
RIT groups was found to be very low compared to that in
the control, ADA, and ETA groups, suggesting that these
BAs inhibited osteocyte proliferation (p < 0.01 [p = 0.0000]).
The results of proliferation test at the 60th hour showed
no proliferation in all BA groups, while proliferation in
the control group was continued (p < 0.01 [p = 0.0000]).
Discussion
The effectiveness of BAs in rheumatic diseases has been
investigated since 2006, but still, there are only a few stud-
ies involving toxicity-related pre-clinical analyses which
have been performed up to date [18]. The present study
aimed to contribute to literature regarding the compara-
tive toxic effects of BAs on osteochondral tissues.
With the development of therapeutics and the ad-
vancement of regenerative medicine, research into the
molecular toxicity of medicines [19] and methods to re-
store damaged tissues [20] has increased dramatically.
With the aim of protecting or restoring chondrocytes
and osteocytes in the context of orthopedic surgery,
studies have focused on tissue engineering, consistent
with many other medical fields [13, 19, 21].
Recently, molecular toxicity analyses of drugs have in-
creased in popularity [8–11, 22–25]. Orthopedic researchalso was influenced from this trend topic. The toxic effects
of drugs on healthy chondrocytes and osteocytes have also
been investigated, and researchers asserted the potential
chondrotoxicity/osteotoxicity [26–29].
Although the BAs are normally brought to the market
for oncology, after FDA’s approval in cases where the
DMARDs are insufficient in rheumatic diseases, it began
to be commonly prescribed. Especially in the active
period of rheumatic diseases, these agents used to sup-
press inflammation, side effects, and/or adverse effects
were encountered in literature [3, 8–11].
Even if a number of clinical studies especially in
terms of side effects of BAs used in our study exist, we
could not find in vitro experimental studies indicating
effects on the articular cartilage and bone tissue in lit-
erature. In addition, to our best knowledge, any study
comparing the effects of BAs on cell viability and prolifer-
ation of chondrocytes and osteocytes lacks in the litera-
ture. However, most reports up to date are based on
experimental animal models, those comprising animal tis-
sues [19]. Although studies based on animal models high-
light differences between human and animal tissues,
researchers may interpret data differently and draw differ-
ing conclusions [19].
Primary human chondrocytes and osteocytes obtained
from osteochondral tissue explants have been used in ex-
perimental processes in this study. Studies using primary
cultures are valuable since cell cultures contain all types of
Fig. 5 (See legend on next page.)
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Fig. 5 Morphological evaluation of cell surfaces. ESEM images of control group, chondrocyte, and osteocyte cultures (a, b, c, and d are ×1000,
×5000, ×10,000, and ×20,000 magnification of chondrocyte, respectively; e, f, g, and h are ×3000, ×5000, ×25,000, and ×50,000 magnification of
osteocyte, respectively). ESEM images of chondrocytes after 24 and 48 h BAs application (magnification ×10,000) and osteocytes after 24 and 48 h
following the administration of BAs (magnification ×5000)
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nents. The only limitations of such studies are the adjust-
ment of the drug dose which will be applied to the culture
medium. As it is well known, for systemically adminis-
tered drugs, it is accepted that the concentration of drug
is equal in all tissues and is metabolized at the same dose
rate according to the virtual volume distribution rules [30,
31]. So, in primary chondrocytes and osteocytes explant
cultures, we considered the dosages tested on other tissues
and reached a peak concentration in the blood [32, 33].
In the present study, we aimed to observe the effects of
three TNF inhibitors, ETA (soluble TNF receptor fusion
protein (p75-IgG fusion protein), INF (chimeric anti-TNF
monoclonal antibody), and ADA (recombinant human
IgG1 monoclonal antibody), and two IL-1 antagonists,
ABA (CTLA4-IgG1 fusion protein) and RIT (anti-CD20
monoclonal antibody; used in B-cell-inhibiting treatments)
on human primary chondrocyte and osteocyte cultures.
An additional aim was to evaluate the toxicity and effects
of these BAs on the viability and proliferation of the cells
in question.Fig. 6 Cartilage and bone cell viability (MTT assay; 540-nm absorbance)Owing to difficulty in isolating osteocytes from the
bone tissue, characterization of osteocytes and chon-
drocytes via immunoflow cytometry was performed be-
fore their use in the experiments. Immunophenotypic
characterization of these cells is usually performed on
expanded cells rather than primary cell cultures. Al-
though no perfect marker has been defined for cells
grown in culture, it is known that hematopoietic
markers, such as CD34, CD14, and CD45, are not
expressed. CD44, a receptor for ligands such as hyalur-
onan and osteopontin, is a marker of osteocytes, but
there is no such a specific receptor for chondrocytes
[17, 34]. For this reason, CD71, CD73, and CD105,
which are typical markers with well-characterized ex-
pression, especially mesenchymal stem cells, were uti-
lized [16].
Pharmacological alternatives of BAs used in this study,
including bevacizumab, ranibizumab, aflibercept, and
Ziv-aflibercept were studied on different tissues, and
mild mitochondrial toxicity was reported [11]. Further-
more, the anti-TNF-α agent anakinra was tested, and the
Fig. 7 Cartilage and bone cell proliferation (MTT assay; 570-nm absorbance)
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stated [23]. However, to our knowledge, there exists no
in vitro study in the literature comparing the molecular
effects of TNF inhibitors, IL-1 antagonists, and B-cell-
depleting BAs on the viability, toxicity, and proliferation
of chondrocytes and osteocytes.
The cases included in the study were those which
confirm that the toxicity in osteocytes and chondro-
cytes was a result of BA therapy and not a patient-
specific cellular response; we ensured that the patients
from whom the tissue samples were provided were not
exposed to methotrexate, fludarabine, cyclophospha-
mide, high-dose steroids, and/or an anti-pneumococcal
vaccination, and that they did not have protein allergies
or a history of RA.
In the present study, the data obtained at the 24 h
showed that the number of live cells and the rate of chon-
drocyte proliferation were highest in the RIT group, and
that ABA and INF were the most toxic to chondrocytes.
However, at the 48 h, neither viable cells nor proliferation
were observed in all groups, except the control (p < 0.01
[p = 0.0000]).
At the 24 h, the highest number of viable osteocytes
was in the ADA group, followed by the ETA group. But,
viability rates in the ABA, INF, and RIT groups werelower. Based on the proliferation analyses at the 48 h,
similar to the chondrocyte cultures, there were no viable
osteocytes and proliferation in all groups, except for the
control. Osteotoxicity was highest in the RIT group,
followed by the INF group (p < 0.01 [p = 0.0000]).
In all groups exposed to BAs for 24 h, when compared
with the control group, MTT results showed that cell vi-
tality decreases. For the same group of cells, when
inverted light microscopy and ESEM images are evalu-
ated together, a decrease in the number of viable cell
concentration is observed compared to the control
group. In addition, when images are examined, changed
cell morphology, loss of the specific cell shape, and de-
tachment from the extracellular matrix formed in the
culture vessel are observed. The remaining live cells could
not divide or proliferate after BA administration. The 48-h
BA application completely inhibited vitality and prolifera-
tion of chondrocytes and osteocytes. Beyond morphological
observations, statistical analysis of MTT data supports this
data and was significant.
Conclusion
RIT and ADA were found to be the least toxic biologics
for cartilage, whereas ADA and ETA were the least toxic
for bone cells (p < 0.01 [p = 0.0000]). Tested doses are
Isyar et al. Journal of Orthopaedic Surgery and Research  (2015) 10:118 Page 10 of 11determined based on the previous studies and systemic
peak levels of patients. Our data indicate that chondro-
toxicity and osteotoxicity of BAs should be taken into
consideration on the treatment regimen during active in-
flammation periods.
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